我国60岁及以上老年男性衰弱与良性前列腺增生/下尿路症状发生风险的相关性

doi:10.3969/j.issn.1003-9198.2026.04.001

摘要/Abstract

摘要： 目的探索我国60岁及以上老年男性衰弱与良性前列腺增生/下尿路症状(benign prostatic hyperplasia/lower urinary tract symptoms,BPH/LUTS)发生风险之间的潜在关联。方法收集中国健康与养老追踪调查项目2011年调查的年龄≥60岁老年男性的人口统计学信息、健康相关数据和检验数据,比较BPH/LUTS和非BPH/LUTS人群的基线特征。通过单因素和多因素logistic回归模型,评估衰弱与BPH/LUTS发生风险的相关性,并进一步采用基于代谢综合征、肥胖和肌少症3个分组变量的亚组分析,探索衰弱与BPH/LUTS的关联在各亚组中的潜在变异。结果本研究最终纳入1453名研究对象,其中BPH/LUTS的患病率为14.66%。在调整所有协变量的模型4中,衰弱前期(OR=1.947,95%CI:1.279~2.964,P=0.002)和衰弱(OR=1.820,95%CI:1.100~3.012,P=0.020)与更高的BPH/LUTS发生风险相关。亚组分析表明,在无代谢综合征的人群中,衰弱前期和衰弱均与更高的BPH/LUTS风险显著相关。结论在我国60岁及以上的老年男性中,衰弱与更高的BPH/LUTS发生风险显著相关,此关联在无代谢综合征的人群中更明显。

关键词: 老年人, 衰弱, 良性前列腺增生/下尿路症状, 中国健康与养老追踪调查项目

Abstract: Objective To explore the association between frailty and the risk of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) in elderly men aged≥60 years old in China. Methods The demographic information, health-related data, and examination data of elderly men aged ≥60 years old in the China Health and Retirement Longitudinal Study in 2011 were collected. Baseline characteristics of the BPH/LUTS group and non-BPH/LUTS group were compared. The correlation between frailty and the risk of BPH/LUTS was evaluated using univariable and multivariate logistic regression models. Subgroup analysis based on three variables including metabolic syndrome, obesity, and sarcopenia, was conducted to explore the potential variations of the association between frailty and BPH/LUTS in each subgroup. Results A total of 1453 subjects were included in this study. The prevalence of BPH/LUTS was 14.66%. After adjusting for all covariates, pre-frailty (OR=1.947, 95%CI: 1.279-2.964, P=0.002) and frailty (OR=1.820, 95%CI: 1.100-3.012, P=0.020) were associated with a higher risk of BPH/LUTS. Subgroup analysis indicated that in the population without metabolic syndrome, pre-frailty and frailty were significantly associated with a higher risk of BPH/LUTS. Conclusions In elderly men aged ≥60 years old in China, frailty is significantly associated with a higher risk of BPH/LUTS, and this association is more obvious in the population without metabolic syndrome.

Key words: aged, frailty, benign prostatic hyperplasia/lower urinary tract symptoms, China Health and Retirement Longitudinal Study

中图分类号:

R 691.2

姬俊杰, 周忠涵, 刘功岳, 刘一茜, 廖利民. 我国60岁及以上老年男性衰弱与良性前列腺增生/下尿路症状发生风险的相关性[J]. 实用老年医学, 2026, 40(4): 325-331.

JI Junjie, ZHOU Zhonghan, LIU Gongyue, LIU Yixi, LIAO Limin. Correlation between frailty and the risk of benign prostatic hyperplasia/lower urinary tract symptoms in elderly males aged 60 and above in China[J]. Practical Geriatrics, 2026, 40(4): 325-331.

参考文献

[1] LERNER L B, MCVARY K T, BARRY M J, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia:AUA GUIDELINE PART Ⅱ-Surgical Evaluation and Treatment[J]. J Urol, 2021, 206(4):818-826.
[2] NGUYEN D D, LI T, FERREIRA R, et al. Ablative minimally invasive surgical therapies for benign prostatic hyperplasia:a review of Aquablation, Rezum, and transperineal laser prostate ablation[J]. Prostate Cancer Prostatic Dis, 2024, 27(1):22-28.
[3] LIU T T, PASCAL L E, RICKE E A, et al. Estrogen regulation in the prostate underlies racial disparity in men with benign prostatic hyperplasia[J]. J Pathol, 2026, 268(2):176-187.
[4] WANG W, GUO Y, ZHANG D, et al. The prevalence of benign prostatic hyperplasia in mainland China:evidence from epidemiological surveys[J]. Sci Rep, 2015, 5:13546.
[5] YE L, LIANG R, LIU X, et al. Frailty and sarcopenia:a bibliometric analysis of their association and potential targets for intervention[J]. Ageing Res Rev, 2023, 92:102111.
[6] QIU Y, LI G, WANG X, et al. Prevalence of multidimensional frailty among community-dwelling older adults:a systematic review and meta-analysis[J]. Int J Nurs Stud, 2024, 154:104755.
[7] TREACY D, HASSETT L, SCHURR K, et al. Mobility training for increasing mobility and functioning in older people with frailty[J]. Cochrane Database Syst Rev, 2022, 6(6):CD010494.
[8] VERONESE N, CUSTODERO C, CELLA A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings:a systematic review and meta-analysis[J]. Ageing Res Rev, 2021, 72:101498.
[9] IMAM T, KONSTANT-HAMBLING R, FLUCK R, et al. The hospital frailty risk score-outcomes in specialised services[J]. Age Ageing, 2021, 50(2):511-518.
[10] CAO X, YANG Z, LI X, et al. Association of frailty with the incidence risk of cardiovascular disease and type 2 diabetes mellitus in long-term cancer survivors:a prospective cohort study[J]. BMC Med, 2023, 21(1):74.
[11] TAYLOR-ROWAN M, HAFDI M, DROZDOWSKA B, et al. Physical and brain frailty in ischaemic stroke or TIA:shared occurrence and outcomes. A cohort study[J]. Eur Stroke J, 2023, 8(4):1011-1020.
[12] YANG H, OU F, CHANG Q, et al. Physical frailty, genetic predisposition, and the risks of severe non-alcoholic fatty liver disease and cirrhosis:a cohort study[J]. J Cachexia Sarcopenia Muscle, 2024, 15(4):1491-1500.
[13] BAUER S R, WALTER L C, ENSRUD K E, et al. Assessment of frailty and association with progression of benign prostatic hyperplasia symptoms and serious adverse events among men using drug therapy[J]. JAMA Netw Open, 2021, 4(11):e2134427.
[14] KÖNIG M, MALSCH C, MARIÑO J, et al. Nocturia as a clinical marker of loss of function and resilience or risk factor for frailty in older adults? Results of the Berlin Aging Study II[J]. Geroscience, 2025, 47(3):4139-4151.
[15] HE D, LI J, LI Y, et al. Frailty is associated with the progression of prediabetes to diabetes and elevated risks of cardiovascular disease and all-cause mortality in individuals with prediabetes and diabetes:evidence from two prospective cohorts[J]. Diabetes Res Clin Pract, 2022, 194:110145.
[16] XU W, CAI J, LIU Y, et al. Sarcopenia and frailty among older Chinese adults:Findings from the CHARLS study[J]. PLoS One, 2024, 19(11):e0312879.
[17] ZHANG W, DING Z, PENG Y, et al. LUTS/BPH increases the risk of depressive symptoms among elderly adults:a 5-year longitudinal evidence from CHARLS[J]. J Affect Disord, 2024, 367:210-218.
[18] ZHOU Z, LIU G, JI J, et al. Association of sarcopenic obesity with benign prostatic hyperplasia/lower urinary tract symptoms:a nationwide cross-sectional study[J]. Eur Urol Open Sci, 2025, 82:81-87.
[19] ALBERTI K G M M, ZIMMET P, SHAW J, et al. The metabolic syndrome:a new worldwide definition[J]. Lancet, 2005, 366(9491):1059-1062.
[20] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian working group for sarcopenia:2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3):300-307.e2.
[21] WANG J, SUN Y X, XIANG S, et al. The association between blood heavy metals and gallstones:a cross-sectional study[J]. Sci Total Environ, 2023, 904:166735.
[22] ABREU W, TOLSON D, JACKSON G A, et al. The relationship between frailty, functional dependence, and healthcare needs among community-dwelling people with moderate to severe dementia[J]. Health Soc Care Community, 2019, 27(3):642-653.
[23] DIDIER J, DE LANDTSHEER S, PACHECO M P, et al. Clinical data-driven classification of pre-frailty reveals sex-specific patterns - Data from the Berlin Aging Study II (BASE-II)[J]. Mech Ageing Dev, 2025, 228:112114.
[24] BAUER S R, SCHERZER R, SUSKIND A M, et al. Co-occurrence of lower urinary tract symptoms and frailty among community-dwelling older men[J]. J Am Geriatr Soc, 2020, 68(12):2805-2813.
[25] BAUER S R, MCCULLOCH C E, CAWTHON P M, et al. Longitudinal associations between concurrent changes in phenotypic frailty and lower urinary tract symptoms among older men[J]. J Frailty Aging, 2023, 12(2):117-125.
[26] BELLOS T C, TZELVES L I, MANOLITSIS I S, et al. Frailty and benign prostatic hyperplasia:the thrilling underlying impact[J]. Arch Ital Urol Androl, 2022, 94(3):345-349.
[27] REN X, WANG J, WANG Z, et al. Frailty as a risk marker of adverse lower urinary symptom outcomes in patients with benign prostatic hyperplasia undergoing transurethral resection of prostate[J]. Front Med:Lausanne, 2023, 10:1185539.
[28] PARKER-AUTRY C Y, BAUER S, FORD C, et al. Examining the role of frailty on treatment patterns and complications among older women undergoing procedure-based treatment for urinary incontinence[J]. J Gerontol A Biol Sci Med Sci, 2024, 79(6):glae027.
[29] BROMAN M M, LANMAN N A, VICKMAN R E, et al. Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia[J]. Front Immunol, 2025, 16:1585446.
[30] FU X, WANG Y, LU Y, et al. Association between metabolic syndrome and benign prostatic hyperplasia:the underlying molecular connection[J]. Life Sci, 2024, 358:123192.
[31] GU M, GE J, XU H, et al. Arctigenin inhibits high glucose-induced EMT and cell proliferation to alleviate benign prostatic hyperplasia companied with type 2 diabetes mellitus through MBOAT4/acylated Ghrelin/GHS-R[J]. Chem Biol Interact, 2025, 418:111601.
[32] YANG T, QIU Z, SHEN J, et al. 17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostatic hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation[J]. J Pharm Anal, 2024, 14(9):100962.
[33] SI H, JIN Y, QIAO X, et al. Predictive performance of 7 frailty instruments for short-term disability, falls and hospitalization among Chinese community-dwelling older adults:a prospective cohort study[J]. Int J Nurs Stud, 2021, 117:103875.
[34] CHEN W, MAN S, WANG B, et al. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia:a cohort study of Chinese elderly males[J]. Low Urin Tract Symptoms, 2022, 14(3):170-177.